Cecchetto Giovanni, Mosseri Veronique, De Bernardi Bruno, Helardot Pierre, Monclair Tom, Costa Elisa, Horcher Ernst, Neuenschwander Sylvia, Tomà Paolo, Rizzo Antonino, Michon Jean, Holmes Keith
Division of Pediatric Surgery, Department of Pediatrics, University of Padova, Italy.
J Clin Oncol. 2005 Nov 20;23(33):8483-9. doi: 10.1200/JCO.2005.02.4661.
Although tumor resection is the mainstay of treatment for localized neuroblastoma, there are no established guidelines indicating which patients should be operated on immediately and which should undergo surgery after tumor reduction with chemotherapy. In an effort to develop such guidelines, the LNESG1 study defined surgical risk factors (SRFs) based on the imaging characteristics.
A total of 905 patients with suspected localized neuroblastoma were registered by 10 European countries between January 1995 and October 1999; 811 of 905 patients were eligible for this analysis.
Information on SRFs was obtained for 719 of 811 patients; 367 without and 352 with SRFs. Of these 719 patients, 201 patients (four without and 197 with SRFs) underwent biopsy only. An attempt at tumor excision was made in 518 patients: 363 of 367 patients without and 155 of 352 patients with SRFs (98.9% v 44.0%). Complete excision was achieved in 271 of 363 patients without and in 72 of 155 patients with SRF (74.6% v 46.4%), near-complete excision was achieved in 81 and 61 patients (22.3% v 39.3%), and incomplete excision was achieved in 11 and 22 patients (3.0% v 14.2%), respectively. There were two surgery-related deaths. Nonfatal surgery-related complications occurred in 45 of 518 patients (8.7%) and were less frequent in patients without SRFs (5.0% v 17.4%). Associated surgical procedures were also less frequent in patients without SRFs (1.6% v 9.7%).
The adoption of SRFs as predictors of adverse surgical outcome was validated because their presence was associated with lower complete resection rate and greater risk of surgery-related complications. Additional studies aiming to better define the surgical approach to localized neuroblastoma are warranted.
尽管肿瘤切除是局限性神经母细胞瘤治疗的主要手段,但目前尚无既定指南表明哪些患者应立即接受手术,哪些患者应在化疗使肿瘤缩小后再进行手术。为制定此类指南,LNESG1研究基于影像学特征定义了手术风险因素(SRF)。
1995年1月至1999年10月期间,10个欧洲国家共登记了905例疑似局限性神经母细胞瘤患者;905例患者中有811例符合本分析条件。
811例患者中有719例获得了SRF信息;367例无SRF,352例有SRF。在这719例患者中,201例患者(4例无SRF,197例有SRF)仅接受了活检。518例患者尝试进行肿瘤切除:367例无SRF的患者中有363例,352例有SRF的患者中有155例(98.9%对44.0%)。363例无SRF的患者中有271例实现了完全切除,155例有SRF的患者中有72例(74.6%对46.4%);81例和61例患者实现了近完全切除(22.3%对39.3%),11例和22例患者分别实现了不完全切除(3.0%对14.2%)。有2例与手术相关的死亡。518例患者中有45例发生了非致命性手术相关并发症(8.7%),无SRF的患者中并发症发生率较低(5.0%对17.4%)。无SRF的患者中相关手术操作也较少见(1.6%对9.7%)。
采用SRF作为不良手术结局的预测指标得到了验证,因为其存在与较低的完全切除率和较高的手术相关并发症风险相关。有必要开展进一步研究以更好地确定局限性神经母细胞瘤的手术方法。